In this review, we advance a new concept in developing vaccines and/or drugs to target speci?c proteins expressed during the early stage of Bacillus anthracis (an- thrax) infection and address existing challenges to t...In this review, we advance a new concept in developing vaccines and/or drugs to target speci?c proteins expressed during the early stage of Bacillus anthracis (an- thrax) infection and address existing challenges to this concept. Three proteins (immune inhibitor A, GPR-like spore protease, and alanine racemase) initially identi?ed by proteomics in our laboratory were found to have di?erential expres- sions during anthrax spore germination and early outgrowth. Other studies of di?erent bacillus strains indicate that these three proteins are involved in either germination or cytotoxicity of spores, suggesting that they may serve as potential targets for the design of anti-anthrax vaccines and drugs.展开更多
基金This work was supported by National Institutesof Health Grants (1-R21-AI58002-01, R01-CA79820,R01-AI50150, P30-AR050948, 1-R43-AI-47558-01A2and R01 CA86172-01), a Dermatology FoundationGrant, a VA Grant 18-103-02, an Office of NavalResearch Grant N00014-01-1-0945, a Department ofDefense Grant APN 07363, a SERCEB grant 5 U54AI057157-02, and the UAB Comprehensive CancerCenter of USA.
文摘In this review, we advance a new concept in developing vaccines and/or drugs to target speci?c proteins expressed during the early stage of Bacillus anthracis (an- thrax) infection and address existing challenges to this concept. Three proteins (immune inhibitor A, GPR-like spore protease, and alanine racemase) initially identi?ed by proteomics in our laboratory were found to have di?erential expres- sions during anthrax spore germination and early outgrowth. Other studies of di?erent bacillus strains indicate that these three proteins are involved in either germination or cytotoxicity of spores, suggesting that they may serve as potential targets for the design of anti-anthrax vaccines and drugs.
